Biodesix Inc.

BDSX Nasdaq SEC CIK 1439725
Follow Biodesix Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $24M +10.4% vs same quarter last year
Net income −$8M +7.8% vs same quarter last year
EPS, diluted −$0.75 +35.3% vs same quarter last year
Operating cash flow −$7.2M +18.9% vs same quarter last year
Revenue by quarter
$20.4M
$18M
$20M
$21.8M
$28.8M
$25.6M
$26.9M
$24M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$88.5M−$35.3M
FY24$71.3M−$42.9M
FY23$49.1M−$52.1M
FY22$38.2M−$65.4M
FY21$54.5M−$43.2M
FY20$45.6M−$65.4M
FY19$24.6M−$30.7M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−200%−150%−100%−50%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−31.5%−39.9%
FY24−48.4%−60.2%
FY23−84.2%−106.2%
FY22−132.4%−171.3%
FY21−75.1%−79.2%
FY20−50.3%−143.7%
FY19−108.9%−125.1%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$23.5M
FY24−$51.9M
FY23−$45.8M
FY22−$48.3M
FY21−$30.5M
FY20−$23.3M
FY19−$23M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Biodesix
  • Healthcare median
−200%−150%−100%−50%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBiodesixHealthcare median
FY25−39.9%−30.6%
FY24−60.2%−47%
FY23−106.2%−58%
FY22−171.3%−80.4%
FY21−79.2%−71.8%
FY20−143.7%−62.2%
FY19−125.1%−46.2%
FY18-−49.6%